BioCentury | Dec 8, 2008
Company News

Visible Genetics, Consolidated Laboratory Services deal

...worldwide marketing rights. Consolidated Laboratory provides diagnostic testing and laboratory services to the pharmaceutical industry. Visible Genetics Inc....
BioCentury | Apr 25, 2005
Company News

Aerogen board of directors update

...Aerogen Inc. (AEGN), Mountain View, Calif. Business: Drug delivery Appointed: Richard Daly, formerly CEO of Visible Genetics Inc. WIR...
BioCentury | Jan 10, 2005
Company News

Vasogen management update

...at Hemosol Corp.; and Marguerite Ethier as general counsel, formerly general counsel at Bayer AG's Visible Genetics Inc....
BioCentury | Mar 15, 2004
Company News

Ciphergen management update

...Diagnostic Hired: William Sullivan as VP of diagnostic operations, formerly VP of diagnostic manufacturing at Visible Genetics Inc. WIR...
BioCentury | Oct 13, 2003
Company News

Cylex management update

...Cylex Inc. , Columbia, Md. Business: Diagnostic Hired: Timothy Ellis as president, formerly COO at Visible Genetics Inc. WIR...
BioCentury | Dec 9, 2002
Finance

Warburg Pincus portfolio

...valued at $130M. Gilead last week announced it will buy VIRS for $464M in cash. Visible Genetics...
...$36M in July 1999, when the Canadian company was valued near $120M. Bayer Diagnostics bought Visible Genetics...
BioCentury | Dec 9, 2002
Finance

Ebb & Flow

...get acquired for cash in the last three months. The other two are Synaptic and Visible Genetics...
...Lundbeck (CSE:LUN) plans to buy SNAP for $121 million in cash, and Bayer Diagnostics bought Visible Genetics...
...which then was valued at $60 million. Warburg invested $36 million in HIV genotyping play Visible Genetics...
BioCentury | Oct 21, 2002
Company News

Visible Genetics, Bayer deal

...VGIN for $61.4 million based on 40.9 million shares at $1.50 (see BioCentury, July 29). Visible Genetics Inc....
BioCentury | Oct 14, 2002
Strategy

3Q deal flow

...biology database Upfront Chromatography Amersham AHM exclusively licenses IP covering expanded bed adsorption (EBA) technologies Visible Genetics...
BioCentury | Sep 9, 2002
Finance

Ebb & Flow

...to trade on the TSE after the deal closes. GNV.U was a founding investor of Visible Genetics...
Items per page:
1 - 10 of 125
BioCentury | Dec 8, 2008
Company News

Visible Genetics, Consolidated Laboratory Services deal

...worldwide marketing rights. Consolidated Laboratory provides diagnostic testing and laboratory services to the pharmaceutical industry. Visible Genetics Inc....
BioCentury | Apr 25, 2005
Company News

Aerogen board of directors update

...Aerogen Inc. (AEGN), Mountain View, Calif. Business: Drug delivery Appointed: Richard Daly, formerly CEO of Visible Genetics Inc. WIR...
BioCentury | Jan 10, 2005
Company News

Vasogen management update

...at Hemosol Corp.; and Marguerite Ethier as general counsel, formerly general counsel at Bayer AG's Visible Genetics Inc....
BioCentury | Mar 15, 2004
Company News

Ciphergen management update

...Diagnostic Hired: William Sullivan as VP of diagnostic operations, formerly VP of diagnostic manufacturing at Visible Genetics Inc. WIR...
BioCentury | Oct 13, 2003
Company News

Cylex management update

...Cylex Inc. , Columbia, Md. Business: Diagnostic Hired: Timothy Ellis as president, formerly COO at Visible Genetics Inc. WIR...
BioCentury | Dec 9, 2002
Finance

Warburg Pincus portfolio

...valued at $130M. Gilead last week announced it will buy VIRS for $464M in cash. Visible Genetics...
...$36M in July 1999, when the Canadian company was valued near $120M. Bayer Diagnostics bought Visible Genetics...
BioCentury | Dec 9, 2002
Finance

Ebb & Flow

...get acquired for cash in the last three months. The other two are Synaptic and Visible Genetics...
...Lundbeck (CSE:LUN) plans to buy SNAP for $121 million in cash, and Bayer Diagnostics bought Visible Genetics...
...which then was valued at $60 million. Warburg invested $36 million in HIV genotyping play Visible Genetics...
BioCentury | Oct 21, 2002
Company News

Visible Genetics, Bayer deal

...VGIN for $61.4 million based on 40.9 million shares at $1.50 (see BioCentury, July 29). Visible Genetics Inc....
BioCentury | Oct 14, 2002
Strategy

3Q deal flow

...biology database Upfront Chromatography Amersham AHM exclusively licenses IP covering expanded bed adsorption (EBA) technologies Visible Genetics...
BioCentury | Sep 9, 2002
Finance

Ebb & Flow

...to trade on the TSE after the deal closes. GNV.U was a founding investor of Visible Genetics...
Items per page:
1 - 10 of 125